GlassScriptPhysician profile
Donald G Smith
NPI 1952388035
$2,861.22
in general payments reported to CMS, 2019-2025
33 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.89 · 2020: $281 · 2021: $460 · 2022: $368 · 2023: $429 · 2024: $548 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.33 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.16 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $298.26 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.24 | 2024-2025 | Caplyta |
| Abbvie INC. | $201.34 | 2021-2025 | Ubrelvy, Mavyret |
| Lilly USA, LLC | $188.01 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $178.78 | 2020-2025 | |
| Eisai INC. | $167.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $150.37 | 2021-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $126.75 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $101.35 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $99.86 | 2019-2025 | |
| Exact Sciences Corporation | $93.45 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $77.96 | 2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $69.23 | 2024-2025 | Fanapt |
| Janssen Biotech, INC. | $63.05 | 2023 | Erleada |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $58.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $52.73 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $42.13 | 2024-2025 | Auvelity |
| Dexcom, INC. | $40.27 | 2023-2024 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $37.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.75 | 2022 | |
| Allergan, INC. | $28.15 | 2019-2020 | |
| Inari Medical, INC. | $25.68 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Aimmune Therapeutics, INC. | $23.88 | 2025 | Zenpep |
| Astellas Pharma US INC | $23.57 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $23.43 | 2024 | |
| Smith+Nephew, INC. | $22.04 | 2025 | Collagenase Santyl |
| Hologic Sales and Service, LLC | $19.75 | 2024 | Aptima |
| E.R. Squibb & Sons, L.L.C. | $18.23 | 2021 | |
| Gilead Sciences, INC. | $16.61 | 2024 | |
| Inspire Medical Systems, INC. | $15.03 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $15.01 | 2020 | |
| Amgen INC. | $14.04 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.